Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDT AustraliaASX:IDT -6.25% Equity-to-Asset is 0.59 as of Dec. 2025, which is 28% below its 10-year median of 0.82. The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, IDT Australia ranks worse than 52.09% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. IDT Australia's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$20.31 Mil. IDT Australia's Total Assets for the quarter that ended in Dec. 2025 was A$34.55 Mil.
Therefore, IDT Australia's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.59.
The historical rank and industry rank for IDT Australia's Equity-to-Asset or its related term are showing as below:
ASX:IDT'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59 Med: 0.82 Max: 0.91
Current: 0.59
During the past 13 years, the highest Equity to Asset Ratio of IDT Australia was 0.91. The lowest was 0.59. And the median was 0.82.
ASX:IDT's Equity-to-Asset is ranked worse than 52.09% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs ASX:IDT: 0.59
IDT Australia (ASX:IDT) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
IDT Australia Equity-to-Asset Related Terms
IDT Australia Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for IDT Australia's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDT Australia Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IDT Australia's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where IDT Australia's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
IDT Australia's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDT Australia (ASX:IDT) has a Equity-to-Asset of 0.59 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IDT Australia and its competitors. This is 28% below median its historical median of 0.82. Over the past decade, IDT Australia's Equity-to-Asset has ranged from 0.59 to 0.91. According to the industry distribution chart, IDT Australia ranks #524 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 52.1%.
Is IDT Australia's Equity-to-Asset too high?
IDT Australia's current Equity-to-Asset of 0.59 is 28% below median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 0.91. The Drug Manufacturers industry median Equity-to-Asset is 0.61. IDT Australia's value of 0.59 is 3.3% below this industry median. Based on the distribution chart, IDT Australia ranks #524 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does IDT Australia's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, IDT Australia ranks #524 out of 1006 companies for Equity-to-Asset. This places IDT Australia in the lower half of its industry. The industry median Equity-to-Asset is 0.61. IDT Australia's value of 0.59 is 3.3% below this benchmark. Historically, IDT Australia's own Equity-to-Asset has ranged from 0.59 to 0.91 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.61, IDT Australia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDT Australia's current Equity-to-Asset of 0.59 is 3.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IDT Australia and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDT Australia's current Equity-to-Asset is 0.59, which is 28% below median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDT Australia stock overvalued right now?
Based on GuruFocus' analysis, IDT Australia (ASX:IDT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.11, compared to a current price of A$0.05 — trading 59.1% below its estimated fair value. The current Equity-to-Asset is 0.59, which is 28% below median its 10-year median of 0.82 and 3.3% below the Drug Manufacturers industry median of 0.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For IDT Australia (ASX:IDT), the current Equity-to-Asset is 0.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services. The company operates in Australia, Asia, Europe, and the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDT has been successfully added to your 
